Zealand Pharma A/S (22Z.F)
Frankfurt · EUR · Healthcare · Biotechnology
€29.98 (+0.13%) as of
Key statistics
- Market cap
- 1.99B
- P/E (TTM)
- 5.95
- EPS (TTM)
- 5.04
- Dividend yield
- 0.00%
- 52-week range
- 29.38 – 73.80
- Beta
- 0.61
- Revenue (TTM)
- 4.64B
- Profit margin
- 59.02%
- Volume
- 200.00
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Søborg, Denmark
- Employees
- 578
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.